25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ARTV (Artiva Biotherapeutics, Inc. Common Stock) Stock Analysis
Buy, Hold or Sell?

Let's analyze Artiva Biotherapeutics, Inc. Common Stock together

I guess you are interested in Artiva Biotherapeutics, Inc. Common Stock. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Artiva Biotherapeutics, Inc. Common Stock’s Financial Insights
  • 📈 Technical Analysis (TA) – Artiva Biotherapeutics, Inc. Common Stock’s Price Targets

I'm going to help you getting a better view of Artiva Biotherapeutics, Inc. Common Stock. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Artiva Biotherapeutics, Inc. Common Stock

I send you an email if I find something interesting about Artiva Biotherapeutics, Inc. Common Stock.

1. Quick Overview

1.1. Quick analysis of Artiva Biotherapeutics, Inc. Common Stock (30 sec.)










1.2. What can you expect buying and holding a share of Artiva Biotherapeutics, Inc. Common Stock? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$6.93
Expected worth in 1 year
$21.03
How sure are you?
12.5%

+ What do you gain per year?

Total Gains per Share
$14.10
Return On Investment
498.1%

For what price can you sell your share?

Current Price per Share
$2.83
Expected price per share
$1.47 - $6.54
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Artiva Biotherapeutics, Inc. Common Stock (5 min.)




Live pricePrice per Share (EOD)
$2.83

2.2. Growth of Artiva Biotherapeutics, Inc. Common Stock (5 min.)




Is Artiva Biotherapeutics, Inc. Common Stock growing?

Current yearPrevious yearGrowGrow %
How rich?$168.7m-$112.2m$203.5m222.9%

How much money is Artiva Biotherapeutics, Inc. Common Stock making?

Current yearPrevious yearGrowGrow %
Making money-$15.3m-$4.5m-$10.8m-70.4%
Net Profit Margin0.0%-1,995.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Artiva Biotherapeutics, Inc. Common Stock (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Artiva Biotherapeutics, Inc. Common Stock?

Welcome investor! Artiva Biotherapeutics, Inc. Common Stock's management wants to use your money to grow the business. In return you get a share of Artiva Biotherapeutics, Inc. Common Stock.

First you should know what it really means to hold a share of Artiva Biotherapeutics, Inc. Common Stock. And how you can make/lose money.

Speculation

The Price per Share of Artiva Biotherapeutics, Inc. Common Stock is $2.83. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Artiva Biotherapeutics, Inc. Common Stock.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Artiva Biotherapeutics, Inc. Common Stock, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.93. Based on the TTM, the Book Value Change Per Share is $3.52 per quarter. Based on the YOY, the Book Value Change Per Share is $-2.39 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Artiva Biotherapeutics, Inc. Common Stock.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.83-29.5%-0.63-22.3%-0.19-6.6%-0.47-16.7%-0.47-16.7%-0.47-16.7%
Usd Book Value Change Per Share-0.73-25.9%3.52124.5%-2.39-84.4%0.8730.6%0.8730.6%0.8730.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.73-25.9%3.52124.5%-2.39-84.4%0.8730.6%0.8730.6%0.8730.6%
Usd Price Per Share3.00-7.13-0.00-3.57-3.57-3.57-
Price to Earnings Ratio-0.90--3.24-0.00--1.62--1.62--1.62-
Price-to-Total Gains Ratio-4.09--6.75--6.75--6.75--6.75-
Price to Book Ratio0.43-0.91-0.00-0.45-0.45-0.45-
Price-to-Total Gains Ratio-4.09--6.75--6.75--6.75--6.75-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.83
Number of shares353
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share3.520.87
Usd Total Gains Per Share3.520.87
Gains per Quarter (353 shares)1,244.09305.69
Gains per Year (353 shares)4,976.381,222.76
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1049764966012231213
2099539942024462436
301492914918036683659
401990619894048914882
502488224870061146105
602985829846073377328
703483534822085598551
803981139798097829774
90447874477401100510997
100497644975001222812220

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.07.00.012.5%1.07.00.012.5%1.07.00.012.5%1.07.00.012.5%
Book Value Change Per Share1.03.00.025.0%1.05.02.012.5%1.05.02.012.5%1.05.02.012.5%1.05.02.012.5%
Dividend per Share0.00.04.00.0%0.00.08.00.0%0.00.08.00.0%0.00.08.00.0%0.00.08.00.0%
Total Gains per Share1.03.00.025.0%1.05.02.012.5%1.05.02.012.5%1.05.02.012.5%1.05.02.012.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Artiva Biotherapeutics, Inc. Common Stock compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.7333.524-121%-2.390+226%0.866-185%0.866-185%0.866-185%
Book Value Per Share--6.9283.749+85%-4.607+166%0.147+4615%0.147+4615%0.147+4615%
Current Ratio--13.93011.312+23%4.294+224%7.266+92%7.266+92%7.266+92%
Debt To Asset Ratio--0.1180.963-88%1.826-94%1.167-90%1.167-90%1.167-90%
Debt To Equity Ratio--0.1330.095+41%-+100%0.047+182%0.047+182%0.047+182%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--216572300.000374360414.333-42%--374360414.333-42%374360414.333-42%374360414.333-42%
Eps---0.834-0.631-24%-0.187-78%-0.472-43%-0.472-43%-0.472-43%
Ev To Ebitda Ratio---2.513-5.110+103%---5.110+103%-5.110+103%-5.110+103%
Free Cash Flow Per Share---0.835-0.625-25%-0.511-39%-0.587-30%-0.587-30%-0.587-30%
Free Cash Flow To Equity Per Share---0.8261.042-179%-0.177-79%0.372-322%0.372-322%0.372-322%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Market Cap68947573.000-6%73089300.000173769810.750-58%-+100%86884905.375-16%86884905.375-16%86884905.375-16%
Net Profit Margin----0%-19.9590%-9.5970%-9.5970%-9.5970%
Operating Margin----0%-20.8080%-10.0390%-10.0390%-10.0390%
Operating Ratio----0%21.808-100%10.539-100%10.539-100%10.539-100%
Pb Ratio0.408-6%0.4330.905-52%-+100%0.453-4%0.453-4%0.453-4%
Pe Ratio-0.849+6%-0.900-3.237+260%--100%-1.619+80%-1.619+80%-1.619+80%
Price Per Share2.830-6%3.0007.133-58%-+100%3.566-16%3.566-16%3.566-16%
Price To Free Cash Flow Ratio-0.847+6%-0.898-3.277+265%--100%-1.639+83%-1.639+83%-1.639+83%
Price To Total Gains Ratio-3.861+6%-4.093-6.747+65%---6.747+65%-6.747+65%-6.747+65%
Quick Ratio--24.72618.801+32%5.287+368%11.383+117%11.383+117%11.383+117%
Return On Assets---0.106-0.105-1%-0.086-19%-0.085-20%-0.085-20%-0.085-20%
Return On Equity---0.120-0.064-47%--100%-0.032-73%-0.032-73%-0.032-73%
Total Gains Per Share---0.7333.524-121%-2.390+226%0.866-185%0.866-185%0.866-185%
Usd Book Value--168783000.00091330750.000+85%-112229333.333+166%3579375.000+4615%3579375.000+4615%3579375.000+4615%
Usd Book Value Change Per Share---0.7333.524-121%-2.390+226%0.866-185%0.866-185%0.866-185%
Usd Book Value Per Share--6.9283.749+85%-4.607+166%0.147+4615%0.147+4615%0.147+4615%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--216572300.000374360414.333-42%--374360414.333-42%374360414.333-42%374360414.333-42%
Usd Eps---0.834-0.631-24%-0.187-78%-0.472-43%-0.472-43%-0.472-43%
Usd Free Cash Flow---20352000.000-15230500.000-25%-12447333.333-39%-14296125.000-30%-14296125.000-30%-14296125.000-30%
Usd Free Cash Flow Per Share---0.835-0.625-25%-0.511-39%-0.587-30%-0.587-30%-0.587-30%
Usd Free Cash Flow To Equity Per Share---0.8261.042-179%-0.177-79%0.372-322%0.372-322%0.372-322%
Usd Market Cap68947573.000-6%73089300.000173769810.750-58%-+100%86884905.375-16%86884905.375-16%86884905.375-16%
Usd Price Per Share2.830-6%3.0007.133-58%-+100%3.566-16%3.566-16%3.566-16%
Usd Profit---20311000.000-15383750.000-24%-4552666.667-78%-11488750.000-43%-11488750.000-43%-11488750.000-43%
Usd Revenue----0%9752333.333-100%3780750.000-100%3780750.000-100%3780750.000-100%
Usd Total Gains Per Share---0.7333.524-121%-2.390+226%0.866-185%0.866-185%0.866-185%
 EOD+3 -5MRQTTM+10 -22YOY+16 -143Y+11 -235Y+11 -2310Y+11 -23

3.3 Fundamental Score

Let's check the fundamental score of Artiva Biotherapeutics, Inc. Common Stock based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.849
Price to Book Ratio (EOD)Between0-10.408
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than124.726
Current Ratio (MRQ)Greater than113.930
Debt to Asset Ratio (MRQ)Less than10.118
Debt to Equity Ratio (MRQ)Less than10.133
Return on Equity (MRQ)Greater than0.15-0.120
Return on Assets (MRQ)Greater than0.05-0.106
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Artiva Biotherapeutics, Inc. Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.729
Ma 20Greater thanMa 502.528
Ma 50Greater thanMa 1002.113
Ma 100Greater thanMa 2002.533
OpenGreater thanClose2.910
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Artiva Biotherapeutics, Inc. Common Stock

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2025-07-21 12:03:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Artiva Biotherapeutics, Inc. Common Stock earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Artiva Biotherapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Artiva Biotherapeutics, Inc. Common Stock:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-1,995.9%+1,995.9%
TTM-5Y-959.7%+959.7%
5Y-959.7%10Y-959.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--88.2%+88.2%
TTM--129.4%+129.4%
YOY-1,995.9%-187.4%-1,808.5%
3Y-959.7%-247.8%-711.9%
5Y-959.7%-337.6%-622.1%
10Y-959.7%-472.4%-487.3%
4.3.1.2. Return on Assets

Shows how efficient Artiva Biotherapeutics, Inc. Common Stock is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Artiva Biotherapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • -10.6% Return on Assets means that Artiva Biotherapeutics, Inc. Common Stock generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Artiva Biotherapeutics, Inc. Common Stock:

  • The MRQ is -10.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.6%TTM-10.5%-0.1%
TTM-10.5%YOY-8.6%-1.8%
TTM-10.5%5Y-8.5%-2.0%
5Y-8.5%10Y-8.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.6%-11.3%+0.7%
TTM-10.5%-11.2%+0.7%
YOY-8.6%-11.3%+2.7%
3Y-8.5%-11.6%+3.1%
5Y-8.5%-11.9%+3.4%
10Y-8.5%-13.6%+5.1%
4.3.1.3. Return on Equity

Shows how efficient Artiva Biotherapeutics, Inc. Common Stock is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Artiva Biotherapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • -12.0% Return on Equity means Artiva Biotherapeutics, Inc. Common Stock generated $-0.12 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Artiva Biotherapeutics, Inc. Common Stock:

  • The MRQ is -12.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -6.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.0%TTM-6.4%-5.6%
TTM-6.4%YOY--6.4%
TTM-6.4%5Y-3.2%-3.2%
5Y-3.2%10Y-3.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.0%-13.2%+1.2%
TTM-6.4%-14.2%+7.8%
YOY--14.3%+14.3%
3Y-3.2%-16.5%+13.3%
5Y-3.2%-17.4%+14.2%
10Y-3.2%-19.5%+16.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Artiva Biotherapeutics, Inc. Common Stock.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Artiva Biotherapeutics, Inc. Common Stock is operating .

  • Measures how much profit Artiva Biotherapeutics, Inc. Common Stock makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Artiva Biotherapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Artiva Biotherapeutics, Inc. Common Stock:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-2,080.8%+2,080.8%
TTM-5Y-1,003.9%+1,003.9%
5Y-1,003.9%10Y-1,003.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.3%+207.3%
TTM--250.3%+250.3%
YOY-2,080.8%-204.2%-1,876.6%
3Y-1,003.9%-214.9%-789.0%
5Y-1,003.9%-328.2%-675.7%
10Y-1,003.9%-441.4%-562.5%
4.3.2.2. Operating Ratio

Measures how efficient Artiva Biotherapeutics, Inc. Common Stock is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Artiva Biotherapeutics, Inc. Common Stock:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY21.808-21.808
TTM-5Y10.539-10.539
5Y10.53910Y10.5390.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.055-2.055
TTM-2.647-2.647
YOY21.8083.043+18.765
3Y10.5393.500+7.039
5Y10.5394.641+5.898
10Y10.5396.340+4.199
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Artiva Biotherapeutics, Inc. Common Stock.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Artiva Biotherapeutics, Inc. Common Stock is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 13.93 means the company has $13.93 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Artiva Biotherapeutics, Inc. Common Stock:

  • The MRQ is 13.930. The company is very able to pay all its short-term debts. +2
  • The TTM is 11.312. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ13.930TTM11.312+2.618
TTM11.312YOY4.294+7.017
TTM11.3125Y7.266+4.046
5Y7.26610Y7.2660.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.9303.612+10.318
TTM11.3123.830+7.482
YOY4.2944.090+0.204
3Y7.2664.639+2.627
5Y7.2665.692+1.574
10Y7.2666.086+1.180
4.4.3.2. Quick Ratio

Measures if Artiva Biotherapeutics, Inc. Common Stock is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Artiva Biotherapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • A Quick Ratio of 24.73 means the company can pay off $24.73 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Artiva Biotherapeutics, Inc. Common Stock:

  • The MRQ is 24.726. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 18.801. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ24.726TTM18.801+5.925
TTM18.801YOY5.287+13.514
TTM18.8015Y11.383+7.418
5Y11.38310Y11.3830.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ24.7262.960+21.766
TTM18.8013.185+15.616
YOY5.2873.776+1.511
3Y11.3834.368+7.015
5Y11.3835.710+5.673
10Y11.3836.289+5.094
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Artiva Biotherapeutics, Inc. Common Stock.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Artiva Biotherapeutics, Inc. Common Stock assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Artiva Biotherapeutics, Inc. Common Stock to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12 means that Artiva Biotherapeutics, Inc. Common Stock assets are financed with 11.8% credit (debt) and the remaining percentage (100% - 11.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Artiva Biotherapeutics, Inc. Common Stock:

  • The MRQ is 0.118. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.963. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.118TTM0.963-0.846
TTM0.963YOY1.826-0.863
TTM0.9635Y1.167-0.203
5Y1.16710Y1.1670.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1180.339-0.221
TTM0.9630.356+0.607
YOY1.8260.335+1.491
3Y1.1670.343+0.824
5Y1.1670.347+0.820
10Y1.1670.382+0.785
4.5.4.2. Debt to Equity Ratio

Measures if Artiva Biotherapeutics, Inc. Common Stock is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Artiva Biotherapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • A Debt to Equity ratio of 13.3% means that company has $0.13 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Artiva Biotherapeutics, Inc. Common Stock:

  • The MRQ is 0.133. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.095. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.133TTM0.095+0.039
TTM0.095YOY-+0.095
TTM0.0955Y0.047+0.047
5Y0.04710Y0.0470.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1330.383-0.250
TTM0.0950.438-0.343
YOY-0.416-0.416
3Y0.0470.452-0.405
5Y0.0470.466-0.419
10Y0.0470.523-0.476
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Artiva Biotherapeutics, Inc. Common Stock generates.

  • Above 15 is considered overpriced but always compare Artiva Biotherapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • A PE ratio of -0.90 means the investor is paying $-0.90 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Artiva Biotherapeutics, Inc. Common Stock:

  • The EOD is -0.849. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.900. Based on the earnings, the company is expensive. -2
  • The TTM is -3.237. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.849MRQ-0.900+0.051
MRQ-0.900TTM-3.237+2.337
TTM-3.237YOY--3.237
TTM-3.2375Y-1.619-1.619
5Y-1.61910Y-1.6190.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.849-2.481+1.632
MRQ-0.900-2.070+1.170
TTM-3.237-2.657-0.580
YOY--3.743+3.743
3Y-1.619-3.711+2.092
5Y-1.619-6.177+4.558
10Y-1.619-6.833+5.214
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Artiva Biotherapeutics, Inc. Common Stock:

  • The EOD is -0.847. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.898. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.277. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.847MRQ-0.898+0.051
MRQ-0.898TTM-3.277+2.379
TTM-3.277YOY--3.277
TTM-3.2775Y-1.639-1.639
5Y-1.63910Y-1.6390.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.847-3.900+3.053
MRQ-0.898-2.798+1.900
TTM-3.277-3.829+0.552
YOY--4.298+4.298
3Y-1.639-5.070+3.431
5Y-1.639-8.476+6.837
10Y-1.639-9.070+7.431
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Artiva Biotherapeutics, Inc. Common Stock is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.43 means the investor is paying $0.43 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Artiva Biotherapeutics, Inc. Common Stock:

  • The EOD is 0.408. Based on the equity, the company is cheap. +2
  • The MRQ is 0.433. Based on the equity, the company is cheap. +2
  • The TTM is 0.905. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.408MRQ0.433-0.025
MRQ0.433TTM0.905-0.472
TTM0.905YOY-+0.905
TTM0.9055Y0.453+0.453
5Y0.45310Y0.4530.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.4082.247-1.839
MRQ0.4331.857-1.424
TTM0.9052.125-1.220
YOY-2.502-2.502
3Y0.4532.485-2.032
5Y0.4533.666-3.213
10Y0.4534.337-3.884
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Artiva Biotherapeutics, Inc. Common Stock.

4.8.3. Insider Transactions

Insiders are holding 19.99% of the shares of Artiva Biotherapeutics, Inc. Common Stock.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-07-22Global Strategic Fund I VenbioBUY41666612
2024-07-22Yong-jun HuhBUY208333212
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets191,263
Total Liabilities22,480
Total Stockholder Equity168,783
 As reported
Total Liabilities 22,480
Total Stockholder Equity+ 168,783
Total Assets = 191,263

Assets

Total Assets191,263
Total Current Assets170,004
Long-term Assets21,259
Total Current Assets
Cash And Cash Equivalents 30,401
Short-term Investments 135,562
Net Receivables 234
Other Current Assets 3,807
Total Current Assets  (as reported)170,004
Total Current Assets  (calculated)170,004
+/-0
Long-term Assets
Property Plant Equipment 20,785
Long-term Assets Other 474
Long-term Assets  (as reported)21,259
Long-term Assets  (calculated)21,259
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities12,204
Long-term Liabilities10,276
Total Stockholder Equity168,783
Total Current Liabilities
Short-term Debt 3,720
Accounts payable 2,036
Other Current Liabilities 6,448
Total Current Liabilities  (as reported)12,204
Total Current Liabilities  (calculated)12,204
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt10,276
Long-term Liabilities  (as reported)10,276
Long-term Liabilities  (calculated)10,276
+/-0
Total Stockholder Equity
Common Stock3
Retained Earnings -266,995
Other Stockholders Equity 435,775
Total Stockholder Equity (as reported)168,783
Total Stockholder Equity (calculated)168,783
+/-0
Other
Capital Stock3
Cash and Short Term Investments 165,963
Common Stock Shares Outstanding 24,342
Liabilities and Stockholders Equity 191,263
Net Debt -16,405
Net Invested Capital 168,783
Net Working Capital 157,800
Property Plant and Equipment Gross 27,319
Short Long Term Debt Total 13,996



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-31
> Total Assets 
0
0
0
105,114
90,161
75,912
225,596
209,581
191,263
191,263209,581225,59675,91290,161105,114000
   > Total Current Assets 
0
0
0
79,821
65,886
49,749
150,565
188,631
170,004
170,004188,631150,56549,74965,88679,821000
       Cash And Cash Equivalents 
0
0
0
53,504
48,200
34,248
55,881
40,235
30,401
30,40140,23555,88134,24848,20053,504000
       Short-term Investments 
0
0
0
23,467
13,934
12,308
90,750
145,193
135,562
135,562145,19390,75012,30813,93423,467000
       Net Receivables 
0
0
0
1,758
1,723
1,461
701
146
234
2341467011,4611,7231,758000
       Other Current Assets 
0
0
0
1,092
2,029
1,732
3,233
3,057
3,807
3,8073,0573,2331,7322,0291,092000
   > Long-term Assets 
0
0
0
25,293
24,275
26,163
75,031
20,950
21,259
21,25920,95075,03126,16324,27525,293000
       Property Plant Equipment 
0
0
0
24,643
23,370
22,735
21,509
20,425
20,785
20,78520,42521,50922,73523,37024,643000
       Long Term Investments 
0
0
0
0
0
0
52,966
0
0
0052,966000000
> Total Liabilities 
0
0
0
267,129
264,834
267,009
24,600
22,940
22,480
22,48022,94024,600267,009264,834267,129000
   > Total Current Liabilities 
0
0
0
12,227
10,368
10,827
13,292
12,253
12,204
12,20412,25313,29210,82710,36812,227000
       Short-term Debt 
0
0
0
3,596
3,647
3,790
3,733
3,740
3,720
3,7203,7403,7333,7903,6473,596000
       Accounts payable 
0
0
0
614
1,483
823
1,215
1,121
2,036
2,0361,1211,2158231,483614000
       Other Current Liabilities 
0
0
0
8,017
5,238
6,214
8,344
7,392
6,448
6,4487,3928,3446,2145,2388,017000
   > Long-term Liabilities 
0
0
0
254,902
254,466
256,182
11,308
10,687
10,276
10,27610,68711,308256,182254,466254,902000
> Total Stockholder Equity
0
0
0
-162,015
-174,673
-191,097
200,996
186,641
168,783
168,783186,641200,996-191,097-174,673-162,015000
   Common Stock
0
0
0
0
0
0
3
3
3
333000000
   Retained Earnings Total Equity000000000
   Accumulated Other Comprehensive Income 
0
0
0
308
207
121
338
-129
0
0-129338121207308000
   Capital Surplus 000000000
   Treasury Stock000000000
   Other Stockholders Equity 
0
0
0
18,988
20,394
21,899
431,244
433,451
435,775
435,775433,451431,24421,89920,39418,988000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue251
Cost of Revenue-0
Gross Profit251251
 
Operating Income (+$)
Gross Profit251
Operating Expense-67,533
Operating Income-67,282-67,282
 
Operating Expense (+$)
Research Development50,328
Selling General Administrative17,205
Selling And Marketing Expenses0
Operating Expense67,53367,533
 
Net Interest Income (+$)
Interest Income5,349
Interest Expense-0
Other Finance Cost-0
Net Interest Income5,349
 
Pretax Income (+$)
Operating Income-67,282
Net Interest Income5,349
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-58,493-76,071
EBIT - interestExpense = -67,282
-58,493
-58,493
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-67,282-58,493
Earnings Before Interest and Taxes (EBITDA)-64,851
 
After tax Income (+$)
Income Before Tax-58,493
Tax Provision-0
Net Income From Continuing Ops-58,493-58,493
Net Income-58,493
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses67,533
Total Other Income/Expenses Net8,789-5,349
 

Technical Analysis of Artiva Biotherapeutics, Inc. Common Stock
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Artiva Biotherapeutics, Inc. Common Stock. The general trend of Artiva Biotherapeutics, Inc. Common Stock is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Artiva Biotherapeutics, Inc. Common Stock's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Artiva Biotherapeutics, Inc. Common Stock Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Artiva Biotherapeutics, Inc. Common Stock.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.71 < 4.95 < 6.54.

The bearish price targets are: 2.55 > 2.19 > 1.47.

Know someone who trades $ARTV? Share this with them.👇

Artiva Biotherapeutics, Inc. Common Stock Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Artiva Biotherapeutics, Inc. Common Stock. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Artiva Biotherapeutics, Inc. Common Stock Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Artiva Biotherapeutics, Inc. Common Stock. The current macd is 0.30601725.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Artiva Biotherapeutics, Inc. Common Stock price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Artiva Biotherapeutics, Inc. Common Stock. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Artiva Biotherapeutics, Inc. Common Stock price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Artiva Biotherapeutics, Inc. Common Stock Daily Moving Average Convergence/Divergence (MACD) ChartArtiva Biotherapeutics, Inc. Common Stock Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Artiva Biotherapeutics, Inc. Common Stock. The current adx is 38.39.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Artiva Biotherapeutics, Inc. Common Stock shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Artiva Biotherapeutics, Inc. Common Stock Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Artiva Biotherapeutics, Inc. Common Stock. The current sar is 3.62824576.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Artiva Biotherapeutics, Inc. Common Stock Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Artiva Biotherapeutics, Inc. Common Stock. The current rsi is 57.73. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Artiva Biotherapeutics, Inc. Common Stock Daily Relative Strength Index (RSI) ChartArtiva Biotherapeutics, Inc. Common Stock Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Artiva Biotherapeutics, Inc. Common Stock. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Artiva Biotherapeutics, Inc. Common Stock price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Artiva Biotherapeutics, Inc. Common Stock Daily Stochastic Oscillator ChartArtiva Biotherapeutics, Inc. Common Stock Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Artiva Biotherapeutics, Inc. Common Stock. The current cci is 44.07.

Artiva Biotherapeutics, Inc. Common Stock Daily Commodity Channel Index (CCI) ChartArtiva Biotherapeutics, Inc. Common Stock Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Artiva Biotherapeutics, Inc. Common Stock. The current cmo is 9.29846776.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Artiva Biotherapeutics, Inc. Common Stock Daily Chande Momentum Oscillator (CMO) ChartArtiva Biotherapeutics, Inc. Common Stock Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Artiva Biotherapeutics, Inc. Common Stock. The current willr is -52.69461078.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Artiva Biotherapeutics, Inc. Common Stock is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Artiva Biotherapeutics, Inc. Common Stock Daily Williams %R ChartArtiva Biotherapeutics, Inc. Common Stock Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Artiva Biotherapeutics, Inc. Common Stock.

Artiva Biotherapeutics, Inc. Common Stock Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Artiva Biotherapeutics, Inc. Common Stock. The current atr is 0.27509899.

Artiva Biotherapeutics, Inc. Common Stock Daily Average True Range (ATR) ChartArtiva Biotherapeutics, Inc. Common Stock Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Artiva Biotherapeutics, Inc. Common Stock. The current obv is 10,957,952.

Artiva Biotherapeutics, Inc. Common Stock Daily On-Balance Volume (OBV) ChartArtiva Biotherapeutics, Inc. Common Stock Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Artiva Biotherapeutics, Inc. Common Stock. The current mfi is 60.95.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Artiva Biotherapeutics, Inc. Common Stock Daily Money Flow Index (MFI) ChartArtiva Biotherapeutics, Inc. Common Stock Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Artiva Biotherapeutics, Inc. Common Stock.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-13ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-17STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-27MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-07-10WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-16STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-17STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-22MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-23BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-24STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-31STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Artiva Biotherapeutics, Inc. Common Stock Daily Candlestick Chart
DateCandlestick Pattern
2025-07-28Bearish Engulfing Candle Pattern

6.4. Technical Score

Let's check the technical score of Artiva Biotherapeutics, Inc. Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.729
Ma 20Greater thanMa 502.528
Ma 50Greater thanMa 1002.113
Ma 100Greater thanMa 2002.533
OpenGreater thanClose2.910
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Artiva Biotherapeutics, Inc. Common Stock with someone you think should read this too:
  • Are you bullish or bearish on Artiva Biotherapeutics, Inc. Common Stock? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Artiva Biotherapeutics, Inc. Common Stock? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Artiva Biotherapeutics, Inc. Common Stock

I send you an email if I find something interesting about Artiva Biotherapeutics, Inc. Common Stock.


Comments

How you think about this?

Leave a comment

Stay informed about Artiva Biotherapeutics, Inc. Common Stock.

Receive notifications about Artiva Biotherapeutics, Inc. Common Stock in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.